Discovery of ((S)-5-(Methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone As a Potent and Selective I_Kur Inhibitor

Citations Over TimeTop 13% of 2012 papers

Abstract

Previously disclosed dihydropyrazolopyrimidines are potent and selective blockers of I(Kur) current. A potential liability with this chemotype is the formation of a reactive metabolite which demonstrated covalent binding to protein in vitro. When substituted at the 2 or 3 position, this template yielded potent I(Kur) inhibitors, with selectivity over hERG which did not form reactive metabolites. Subsequent optimization for potency and PK properties lead to the discovery of ((S)-5-(methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone (13j), with an acceptable PK profile in preclinical species and potent efficacy in the preclinical rabbit atrial effective refractory period (AERP) model.

Related Papers

• → Association of the hERG mutation with long-QT syndrome type 2, syncope and epilepsy(2016)19 cited
• → Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel(2005)39 cited
• → Identification and characterization of a novel genetic mutation with prolonged QT syndrome in an unexplained postoperative death(2013)10 cited
• → Robust Deep Learning Architecture for hERG-related Cardiotoxicity Prediction on Small-Scale Dataset(2022)